Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data

被引:6
作者
Pisc, Julia [1 ]
Ting, Angela [2 ]
Skornicki, Michelle [1 ]
Sinno, Omar [2 ]
Lee, Edward [2 ]
机构
[1] Aetion Inc, New York, NY 10001 USA
[2] UCB Pharma, Atlanta, GA 30080 USA
关键词
commercial; database; disease management; healthcare costs; healthcare resource utilization; IBM (R) MarketScan (R); Medicaid; Medicare; real-world data; treatment; United States claims database; INTERNATIONAL CONSENSUS GUIDANCE; DOUBLE-BLIND; EFFICACY; SAFETY; MANAGEMENT;
D O I
10.57264/cer-2023-0108
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Aim: There are limited data on the clinical and economic burden of exacerbations in patients with myasthenia gravis (MG). We assessed patient clinical characteristics, treatments and healthcare resource utilization (HCRU) associated with MG exacerbation. Patients & methods: This was a retrospective analysis of adult patients with MG identified by commercial, Medicare or Medicaid insurance claims from the IBM (R) MarketScan (R) database. Eligible patients had two or more MG diagnosis codes, without evidence of exacerbation or crisis in the baseline period (12 months prior to index [first eligible MG diagnosis]). Clinical characteristics were evaluated at baseline and 12 weeks before each exacerbation. Number of exacerbations, MG treatments and HCRU costs associated with exacerbation were described during a 2-year follow-up period. Results: Among 9352 prevalent MG patients, 34.4% (n = 3218) experienced >= 1 exacerbation after index: commercial, 53.0% (n = 1706); Medicare, 39.4% (n = 1269); and Medicaid, 7.6% (n = 243). During follow-up, the mean (standard deviation) number of exacerbations per commercial and Medicare patient was 3.7 (7.0) and 2.7 (4.1), respectively. At least two exacerbations were experienced by approximately half of commercial and Medicare patients with >= 1 exacerbation. Mean total MG-related healthcare costs per exacerbation ranged from $26,078 to $51,120, and from $19,903 to $49,967 for commercial and Medicare patients, respectively. AChEI use decreased in patients with multiple exacerbations, while intravenous immunoglobulin use increased with multiple exacerbations. Conclusion: Despite utilization of current treatments for MG, MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.
引用
收藏
页数:14
相关论文
共 50 条
[41]   Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective [J].
Zhdanava, Maryia ;
Pesa, Jacqueline ;
Boonmak, Porpong ;
Schwartzbein, Samuel ;
Cai, Qian ;
Pilon, Dominic ;
Choudhry, Zia ;
Lafeuille, Marie-Helene ;
Lefebvre, Patrick ;
Souayah, Nizar .
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2024, 22 (05) :735-747
[42]   Treatment Patterns and Healthcare Resource Utilization Among Patients with Atopic Dermatitis: A Retrospective Cohort Study Using German Health Claims Data [J].
Marie Schild ;
Valeria Weber ;
Diamant Thaçi ;
Agnes Kisser ;
Wolfgang Galetzka ;
Dirk Enders ;
Franziska Zügel ;
Christoph Ohlmeier ;
Holger Gothe .
Dermatology and Therapy, 2022, 12 :1925-1945
[43]   Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis [J].
Kreuter, Michael ;
Picker, Nils ;
Schwarzkopf, Larissa ;
Baumann, Severin ;
Cerani, Agustin ;
Postema, Roelien ;
Maywald, Ulf ;
Dittmar, Axel ;
Langley, Jonathan ;
Patel, Haridarshan .
RESPIRATORY RESEARCH, 2022, 23 (01)
[44]   Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data [J].
Niegisch, Guenter ;
Grimm, Marc-Oliver ;
Hardtstock, Fraence ;
Krieger, Julia ;
Starry, Alexandra ;
Osowski, Ulrike ;
Deiters, Barthold ;
Maywald, Ulf ;
Wilke, Thomas ;
Kearney, Mairead .
JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) :531-542
[45]   Perioperative Management of Patients With Myasthenia Gravis Undergoing Robotic-Assisted Thymectomy-A Retrospective Analysis and Clinical Evaluation [J].
Scheriau, Georg ;
Weng, Rosa ;
Lassnigg, Andrea ;
Maleczek, Mathias ;
Zimprich, Fritz ;
Matilla, Jose ;
Moser, Bernhard ;
Bernardi, Martin H. .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2022, 36 (10) :3806-3813
[46]   Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study [J].
Hudesman, David P. ;
Chakravarty, Soumya D. ;
Emond, Bruno ;
Ellis, Lorie A. ;
Lefebvre, Patrick ;
Sadik, Kay ;
Scher, Jose U. .
BMC RHEUMATOLOGY, 2020, 4 (01)
[47]   Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study [J].
David P. Hudesman ;
Soumya D. Chakravarty ;
Bruno Emond ;
Lorie A. Ellis ;
Patrick Lefebvre ;
Kay Sadik ;
Jose U. Scher .
BMC Rheumatology, 4
[48]   Healthcare Expenditure and Resource Utilization in Patients with Anaemia and Chronic Kidney Disease: A Retrospective Claims Database Analysis [J].
Wish, Jay ;
Schulman, Kathy ;
Law, Amy ;
Nassar, George .
KIDNEY & BLOOD PRESSURE RESEARCH, 2009, 32 (02) :110-118
[49]   Healthcare resource utilization and costs associated with hepatitis A in the United States: a retrospective database analysis [J].
Samant, Salome ;
Chen, Edith ;
Carias, Cristina ;
Kujawski, Stephanie A. .
JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) :1046-1052
[50]   Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis [J].
Geneviève Gauthier ;
Annie Guérin ;
Maryia Zhdanava ;
William Jacobson ;
George Nomikos ;
Elizabeth Merikle ;
Clément François ;
Vanessa Perez .
BMC Psychiatry, 17